Mode
Text Size
Log in / Sign up
N/A N=13 Randomized Treatment

Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder

Major Depressive Disorder · MDD · Depression

Enrolled (actual)
13
Serious AEs
0.0%
Results posted
May 2021
Primary outcome: Primary: Participant's Desire to Continue Using VR After the Study Ends — 9.54 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Virtual Reality Behavioral Activation (Device); Behavioral Activation in real-life (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Stanford University
Primary completion
Jan 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Participant's Desire to Continue Using VR After the Study Ends
9.54
PRIMARY
Number of Participants Who Dropped Out of Each Study Arm
2; 1; 0
PRIMARY
Participant's Satisfaction With the VR-BA Treatment
12.5
PRIMARY
Participant's Use of the VR Headset
21.7
PRIMARY
Participant's Acceptance of VR-BA Treatment
42.4
PRIMARY
How Well Can Participants Tolerate the VR-BA Treatment?
2.9
PRIMARY
How Present Did Individuals in the VR-BA Treatment Feel?
7.1
SECONDARY
Change in Depression Scores on the PHQ-9 From Baseline to Session 4, Compared Across Three Study Arms
5.7; 3; .25

Summary

The primary purpose of this study is to test the safety and feasibility of virtual reality (VR) technology in the use of behavioral activation (BA) as a treatment for major depressive disorder (MDD). The secondary purpose of this study is to examine whether any evidence of clinical efficacy exists for VR delivered BA.

Eligibility Criteria

Inclusion Criteria

  • Patient must meet DSM V criteria for MDD
  • Patient must be at least 18 years of age
  • Patient must be English speaking

Exclusion Criteria

  • Substance Use Disorders in past year
  • Any psychosis or bipolar I disorder
  • Any seizure in the last 6 months or untreated epilepsy
  • Current nonsuicidal self-injury or parasuicidal behavior
  • Current suicidal urges and intent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04268316). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search